GH Research PLC (GHRS): Market Cap to Earnings and Growth Ratio

Symbol and logo of brand GH Research Group (GHRS)

GH Research PLC develops innovative treatments for mental disorders with the potential for global scaling and a future monopoly on course pricing. The growth company undervaluation metric visualizes market resilience, while the 0.00 value corresponds to the current metric. Developments in psychedelics for treating depression are designed to generate long-term medical rent through unique patents.

GH Research PLC (GHRS): Price/Earnings to Growth Multiple from 07/04/2022 to 11/12/2026

Analytical breakdowns for GH Research PLC (GHRS)

- share price and consensus valuation forecast:
Price Performance Chart GH Research plc|GHRS - Price Target Chart
- stock exchange capitalization data:
Market Valuation GH Research Corp|GHRS - Total Company Value
- balance sheet net asset value indicators:
Net Assets per Share GH Research|GHRS - Company Net Assets|Market-to-Book Ratio ghres.com|GHRS - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio GH Research PLC|GHRS - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital ghres.com|GHRS - Company Debts|Debts to Book Value GH Research Corp|GHRS - Company Long-Term Debts|Short-Term Indebtedness GH Research|Intermediate Coverage Ratio ghres.com
- net income and valuation ratios data:
GHRS - Net Income|Expected Net Income GH Research PLC|GHRS - Price to Earnings Ratio|Future Price to Earnings Multiple GH Research Group|GHRS - PEG Multiple|Company Value to EBITDA GH Research Corp|GHRS - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters GH Research|GHRS - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months ghres.com|GHRS - Earnings growth in current year|Earnings growth forecast for next year GH Research PLC
Fundamental company analysis:GHRS - GH Research plc
Original product of ghres.com

The stability of GH Research PLC (GHRS) relies on venture expectations regarding the success of clinical trials in the field of psychedelic medicine. The PEG ratio determines whether the market value is justified by future development, while the current PEG ratio below one signals that the asset is undervalued, helping investors distinguish a promising breakout from a value trap.

Competing companies

ALKS (Alkermes PLC) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Avadel Pharma AVDL|ATAI (atai) - Market Cap to Earnings and Growth Ratio|MNMD - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income compasspathways.com CMPS|LBRX (LB Pharmaceuticals) - Price/Earnings to Growth Multiple|Price to Earnings Adjusted for Growth Rate Bright Minds Bio (DRUG)|VNDA (Vanda Pharmaceuticals Inc) - PEG Multiple|Price/Earnings to Growth Multiple Cybin Corp (CYBN)|PEG Multiple ANRO|NRXP (nrxpharma.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Cingulate CING|silopharma.com (SILO) - Price to Earnings Adjusted for Growth Rate|China Pharma - PEG Multiple|Price to Net Income Growth Ratio Clearmind Medicine, Inc. (CMND)|PBM: PEG Multiple|scisparc.com - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple SEEL|VRPX: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Karuna (KRTX)